Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
06/16/2017 06/19/2017 06/20/2017 06/21/2017 06/22/2017 Date
1685(c) 1695.5(c) 1693(c) 1683(c) 1722(c) Last
19 969 256 5 867 800 9 651 466 8 008 087 8 526 605 Volume
+0.06% +0.62% -0.15% -0.59% +2.32% Change
More quotes
Financials ( GBP)
Sales 2017 30 187 M
EBIT 2017 8 314 M
Net income 2017 4 337 M
Debt 2017 13 929 M
Yield 2017 4,65%
Sales 2018 31 099 M
EBIT 2018 8 656 M
Net income 2018 4 784 M
Debt 2018 13 212 M
Yield 2018 4,67%
P/E ratio 2017 19,45
P/E ratio 2018 16,98
EV / Sales2017 3,27x
EV / Sales2018 3,15x
Capitalization 84 685 M
More Financials
Company
‘GlaxoSmithKline Plc is a global healthcare company which engages in developing, manufacturing, and marketing of pharmaceutical products including vaccines, over the counter medicines and health-related consumer products.It operates through the following segments: Pharmaceuticals, Pharmaceuticals... 
Sector
Pharmaceuticals
Calendar
07/26Earnings Release
More about the company
Surperformance© ratings of GlaxoSmithKline
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
06/22 GLAXOSMITHKLINE : Reports Findings in DNA Research (Ruthenium Promoted On-DNA Ri..
06/22 GLAXOSMITHKLINE : New Findings from GlaxoSmithKline plc in the Area of HIV/AIDS ..
06/22 RESEARCHERS FROM GLAXOSMITHKLINE PLC : A vaccine...
06/22 GLAXOSMITHKLINE : Study Results from GlaxoSmithKline plc in the Area of Influenz..
06/22 GLAXOSMITHKLINE : reports positive results with its shingles vaccine
06/21DJGLAXOSMITHKLINE : Shingles Treatment Meets Objective in Phase III Trial
06/16 GLAXOSMITHKLINE : GSK announces results from 10-year continuation study showing ..
06/16 Aspen loses Italy appeal over cancer drug prices
06/15 GLAXOSMITHKLINE : Researchers from GlaxoSmithKline plc Report Findings in Vaccin..
More news
Sector news : Pharmaceuticals - NEC
06/22 MYLAN : shareholders vote against executive pay, re-elect board
06/22 Health stocks help European equities cut losses
06/22DJR. JOHNSON : Missouri Sues Drug Firms Over Opioid Marketing -- WSJ
06/21DJJOHNSON & JOHNSON : J&J Seeking Dismissal of Talc Lawsuits in Missouri
06/21DJR. JOHNSON : Missouri Files Its Own Suit Against Opioid-Painkiller Producers -- ..
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on GLAXOSMITHKLINE 
2015This could be the time to buy
2014Bearish signal below GBp 1415
More Strategies
Latest Tweets
01:10aGlaxoSmithKline wins $235M from Teva in carve-out patent fight over heart dru..
1
06/22GlaxoSmithKline : GSK's new CEO aims to divest sports nutrition brand - sourc.. 
06/21$AGEN: Agenus confirms that GlaxoSmithKline's (GSK) shingles vaccine candidat.. 
06/21Edge Asset Management Inc. Continues to Hold Stake in GlaxoSmithKline PLC $GS.. 
06/21GlaxoSmithKline : Shingles Treatment Meets Objective in Phase III Trial  
More tweets
Qtime:252
News from SeekingAlpha
06/22 Drug stocks rally on GOP draft of healthcare bill
06/22 GILEAD : The Conundrum
06/22 Only Bristol Bucks Big Pharma's Drive For External Reliance
06/21 FDA aims at removing barriers to generic drug competition
06/21 Glaxo's shingles vaccine triggers immune response in elderly patients previou..
Advertisement
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 17,9  GBP
Spread / Average Target 3,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Roy Malcolm Anderson Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE10.24%107 550
JOHNSON & JOHNSON17.10%366 496
NOVARTIS7.69%225 516
ROCHE HOLDING LTD.8.81%225 056
PFIZER4.86%202 832
MERCK AND COMPANY12.15%180 576
More Results